Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder

[cafead]

via CAR-T cell therapy makers are on their way to finding a footing in the autoimmune disease space, and companies like Kyverna Therapeutics are targeting rare disorders with limited treatment options.

article source